Focus Partners Advisor Solutions LLC Has $2.08 Million Holdings in Amgen Inc. $AMGN

Focus Partners Advisor Solutions LLC decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 18.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,234 shares of the medical research company’s stock after selling 1,669 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Amgen were worth $2,083,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Kingsview Wealth Management LLC grew its holdings in shares of Amgen by 1.2% in the 3rd quarter. Kingsview Wealth Management LLC now owns 40,732 shares of the medical research company’s stock valued at $11,495,000 after acquiring an additional 481 shares in the last quarter. 111 Capital acquired a new position in Amgen during the third quarter valued at approximately $1,931,000. Elo Mutual Pension Insurance Co grew its stake in Amgen by 2.3% in the third quarter. Elo Mutual Pension Insurance Co now owns 62,898 shares of the medical research company’s stock valued at $17,750,000 after purchasing an additional 1,417 shares in the last quarter. Cobblestone Capital Advisors LLC NY increased its position in shares of Amgen by 2.1% during the 3rd quarter. Cobblestone Capital Advisors LLC NY now owns 1,731 shares of the medical research company’s stock worth $488,000 after purchasing an additional 35 shares during the last quarter. Finally, Fisher Asset Management LLC raised its stake in shares of Amgen by 91.6% during the 3rd quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company’s stock worth $221,607,000 after purchasing an additional 375,463 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Board declared a $2.52 per‑share dividend for Q2 2026 — a cash return and yield support that tends to be received positively by income and value investors. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Positive Sentiment: Amgen advanced its blinatumomab franchise with a new Phase 3 subcutaneous trial — if successful, a subcutaneous formulation can broaden use, improve patient convenience, and extend commercial life. This is a clinically material development for future revenue potential. Amgen Advances Blinatumomab Franchise With New Phase 3 Subcutaneous Trial
• Positive Sentiment: Stock reached an annual high within a Nasdaq‑100 rally — positive technical momentum and index strength can attract flows and lift shares. Amgen (NASDAQ:AMGN) Hits Annual High Within The Nasdaq 100 Index Rally
• Neutral Sentiment: Broader media and analyst coverage (Zacks, Yahoo Finance pieces) is raising investor attention but contains mainly summaries and guidance rechecks rather than new fundamental catalysts. Increased coverage can boost trading volume and visibility. Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Industry and market reports (asthma market outlook, competitor regulatory moves) are circulating; these are background items to monitor for longer‑term impact but not immediate stock drivers. 7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036
• Neutral Sentiment: Short‑interest entries in recent feeds report a “significant increase” but show zero shares/NaN figures — this appears to be a data error rather than a genuine surge in shorting. Until reliable short‑interest data is available, treat these reports cautiously. (Data entries from March 3–4 appear inconsistent.)

Wall Street Analysts Forecast Growth

AMGN has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft increased their price objective on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a report on Thursday, February 5th. Scotiabank assumed coverage on shares of Amgen in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 price target for the company. Sanford C. Bernstein lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective on the stock. in a research note on Tuesday, January 20th. TD Cowen reiterated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Finally, Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $354.17.

Amgen Stock Up 0.6%

Amgen stock opened at $379.27 on Thursday. The company’s 50-day moving average price is $351.83 and its two-hundred day moving average price is $321.58. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The stock has a market cap of $204.45 billion, a P/E ratio of 26.65, a P/E/G ratio of 3.74 and a beta of 0.45. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business’s revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is currently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.